The cytokine IL‐2 is central to protective immunity and has shown a potent capacity to induce T‐cell growth in vitro and is an FDA‐approved drug for multiple metastatic cancers (Smith, 1988; Hsu et al., 2021). Here, IL2 is linked to metastatic malignant neoplasm.